Catastrophic evolution of trimethoprim resistance by Altınuşak, Tuğçe & Altinusak, Tugce
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
CATASTROPHIC EVOLUTION OF TRIMETHOPRIM RESISTANCE 
 
 
 
 
 
 
 
 
 
 
 
by 
 
TUĞÇE ALTINUŞAK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School of Engineering and Natural Sciences 
in partial fulfillment of 
the requirements for the degree of Master of Science 
 
 
SABANCI UNIVERSITY 
January, 2014 
ii 
 
 
 
CATASTROPHIC EVOLUTION OF TRIMETHOPRIM RESISTANCE 
 
 
  
 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©TUĞÇE ALTINUŞAK, 2014 
ALL RIGHTS RESERVED 
 
 
 
iv 
 
 
ABSTRACT 
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Understanding the molecular basis of antibiotic resistance is of great importance 
since antibiotic resistance is an ever growing public health problem. Pathogenic bacteria 
can accumulate resistance against antibiotics via horizontal gene transfer and 
spontaneous mutations. One of the most prevalent resistance mechanisms is increased 
antibiotic tolerance as a result of spontaneous mutations on the enzymes that are 
targeted by antibiotic molecules. Here, in this study, we investigated how ecological 
factors influence genetic trajectories that lead to antibiotic resistance. In a custom made 
continuous culture device that we call the Morbidostat, we evolved several wild type 
Escherichia coli populations against trimethoprim where six of these populations were 
continuously diluted with a mild dilution factor (~0.3 hour-1) and remaining seven 
populations were continuously diluted with a strong dilution factor (~0.6 hour-1).At the 
end of four weeks, all of the populations evolved to similar levels of trimethoprim 
resistance in a stepwise manner by accumulating three or four mutations on the 
promoter and coding regions of DHFR gene. The first mutation was almost always on 
the promoter region and the following first amino acid replacement on the protein was 
chosen from the sector regions we predicted by Statistical Coupling Analysis (SCA). 
Strikingly, evolutionary trajectories of  the populations that evolved under strong 
dilution were far from predictability and population structures were highly 
heterogeneous. Prolonged clonal interference was abundantly observed in the 
populations evolving under strong dilution. Our results suggest that evolution of 
resistance highly depend on fitness constraints imposed by ecological factors 
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Antibiyotik direnci büyüyen bir sağlık sorunudur bu yüzden antibiyotik 
direncinin moleküler temelini anlamak çok önemlidir. Patojenik bakteriler yatay gen 
transferi yada mutasyon kazanarak antibiyotiklere dirençli hale gelirler. En yaygın 
bulunan direnç mekanizmaları ise antibiyotik moleküllerinin hedef aldığı proteinlerin 
genleri üzerinde meydana gelen mutasyonlardır. Biz bu çalışmada, antibiyotik direncine 
yol açan genetik gidim izlerinin ekolojik faktörlerce nasıl değiştini araştırdık. E.coli 
populasyonlarını “Morbidostat” diye adlandırdığımız  cihazı kullanarak trimetoprime 
karşı dirençli hale getirdik. Altı kültürü hafif seyreltme faktörü(~0.3 saat-1), diğer 7 
kültürü ise kuvvetli seyreltme föktürü (~0.6 saat-1) kullanarak evrimleştirdik. Dört 
haftanın sonunda  bütün populasyonlar DHFR geni üzerinde yada promotorunda oluşan 
mutasyonlar kazanarak adım adım trimetoprim direnci kazandılar. Đlk mutasyon 
çoğunluka promotor bölegisinde, sonraki mutasyonlar ise DHFR’ da aminoasit değişimi 
olarak gözlemlendi. Đlk aminoasit değişimi özellikle SCA analizi sonucunda 
bulduğumuz sektör bölgesinde görülüldü. Ayrıca,Kuvvetli seyreltilme ile evrimleştirilen 
kültür populasyonlarının evrimsel gidim izleri şarşıtıcı bir şekilde heterojen ve 
tahminden uzaktı. Uzun süreçli klonal karışma çoğunlukla kuvvetli seyreltilme ile 
evremleştirilen kültürlerde mevcuttu. Böylece, Trimethoprim direncinin evriminin 
ekolojik faktörlerce gelen fitnes kısıtlamasına bağlı olduğu sonucuna vardık. 
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1. INTRODUCTION 
 
 
1.1 Antibiotics and Antibiotic Classes 
 Antibiotics are small organic molecules that are capable of killing 
microorganisms or inhibiting growth of microorganisms. The term and definition of 
antibiotic is firstly introduced by Selman Waksman who discovered several 
antimicrobial reagents such as streptomycin, actinomycin, streptothricin, gramicidin, 
andbacitracin. However, the dawn of antibiotic era is accepted as the discovery of 
penicillin by Alexander Fleming in 1928.  While Fleming was screening 
Staphylococcus aureus, a bacterial species causing skin infections, food poisoning, and 
respiratory diseases, he noticed a contaminant mold which has been secreting 
antibacterial substance that have killed staphylococcus aureus. Following this 
observation, pure penicillin was produced and used to clear infectious diseases after 
1940 [1, 2]. Since then, several novel antibiotics have been introduced to the market and 
used for medical purposes. Antibiotics are classified in five groups according to 
pathways that they inhibit. These pathways are (1) cell wall synthesis, (2) plasma 
membrane organization, (3) nucleic acid synthesis, (4) ribosomal function, and (5) 
folate synthesis (Figure 1) [3]. 
Cell wall synthesis has a vital role in survival of bacteria. Any damage or loss of 
bacterial cell wall can result in cell lyses and consecutive cell death. Cell wall 
components of gram negative and positive bacteria have some differences but 
peptidoglican layer is the common constituent, which is hence the target of cell wall 
synthesis antibiotics. Cell wall synthesis is carried on in three steps. First step is 
precursor synthesis that is the synthesis of UDP-MurNAc from UDP-GlcNAc with 
series of enzymatic reactions involving MurA to Mur F in cytoplasm. Fosmomycin is 
one antibiotic that targets MurA. Similarly, cycloserine is another drug that binds to 
both alkaline racemase and D-Alannyl-D-Alaline synthetase that are required in the last 
step of MurNAc synthesis. Second step involves transport of MurNAc to cytoplasmic 
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membrane by a lipid carrier. Lipid carrier formation is catalyzed by MraY and MurG 
links MurNAc to lipid molecules.  Bacitracin, for instance, interferes with this step and 
blocks transfer. Final step is subunit polymerization and connection of new 
peptidoglican to cell wall. This step is also a target of β-lactam antibiotics such as 
penicilin, cephalaosporins, penems, carbapenems, and monobactams. 
 
Figure 1: Classification of antibiotics. Antibiotics are classified in five groups according 
to mode of action. Figure is adapted from a reference [3] 
 
Cell membrane is composed of lipid bilayer, proteins and lipoproteins. The main 
duty of cell membrane is regulating transport of ions and molecules. Many antibiotics 
target cell membrane. Polymyxins are one of these antibiotics which disturb the 
negative charge of gram negative bacteria found in lipid surface. This action results 
magnesium and calcium displacement resulting leakage of content of cell.  
 Many antibiotics inhibit nucleic acid synthesis via several mechanisms. 
Flucytosine stops thymidylate synthetase activity and causes thymine deficiency of 
cells. Acyclovoir interferes with thymine kinase and DNA polymerase of herpes virus 
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and Zidovudine inhibits reverse transcriptase enzyme of human immunodeficiency virus 
(HIV). Some intercalating agents are also used to impair DNA function. Although their 
antimicrobial action is debatable, chloroquine and miracil D kill plasmodia and 
schistosomoes. Rifamycin binds to cofactor binding site of RNA polymerase which is 
required for initiation of transcription. The other nucleic acids inhibition mechanism is 
impairing of DNA replication. Nalidixic acid, norfloxacin and ofloxacin belong to 
quinolones antibiotic classes and inhibit DNA gyrase which uncoils DNA during DNA 
replication [3]. 
 Ribosomes synthesize proteins with sequential events of initiation, elongation 
and termination. Ribosome consists of two ribonucleoprotein subunits 30S and 
50Swhich together form 70S initiation complex during protein synthesis. 
Unsurprisingly, both subunits are targets of protein synthesis inhibitors. Amino 
glycosides, a class of protein synthesis inhibitors, have free NH4 and OH groups for 
binding to particular proteins of 30S subunit. For instance, streptomycin, kanamycin, 
and gentamycin bind to16S region of 30S subunit resulting 30S subunit depletion in 
pool and shutdown of protein synthesis. In the case of spectinomycin which is closely 
related to amino glycosides classes, it causes misreading of mRNA code and 
consecutive defective protein synthesis as a consequence of unstable binding of 
peptidyltRNA. Tetracyclin, which is another 30S inhibitor, binds transiently to 
aminoacyl-tRNA and blocks the access to ribosome. Chloramphenicol, erythromycin, 
and clindamycin are 50S subunit inhibitors. Chloramphicol affects both gram negative 
and positive bacteria by binding to peptidlyltransferase and stopping peptide bond 
formation. Erytromycin belongs to macrolides family and is generally more effective 
against gram positive bacteria.  It interferes with peptidyltransferase reaction and 
translocation [3, 4]. 
In folic acid synthesis pathway, both trimethoprim and sulfomides impede 
tetrahydrofolate production which is an important precursor of DNA, RNA and some 
proteins [3, 4]. 
 
 
  
1.2 Antibiotic Resistance 
Before antibiotics discovery, human suffering was 
because of infectious disease
discovery of antibiotics, all 
symptoms and doctors prescribed antibiotics for every patient even their infection was 
not bacterial. Additionally, 
massive use of antibiotics in livestock
prevent disease growth. Therefore, overuse of antibiotics revealed resistance
Bacteria evolve many resistance mechanisms
horizontal gene transfer of 
most observable resistant mechanism is efflux pumps found in membrane of bacteria 
which is responsible for transport of antibiotics to ou
commonly seen in tetracycline resistance. 
molecules so antibiotics cannot bind to its target. In the case of spectinomycin, an 
enzyme chemically modifies spectinomycin molecule. Therefo
to target site. Sometimes, an enzyme degrades antibiotics. For examples, b
enzymes bind to b-lactam ring of penicillin group and cleave rings and antibiotic cannot 
reach to its binding site (Figure 2)
Figure 2: Antibiotic resistance mechanisms in bacteria
4 
enormous. Many people died 
s from tuberculosis to pneumonia, to strep throat
mankinds started to use antibiotics for every little disease 
antibiotics were not only used by humans, there has been 
s such as animal feed and water supply in order to 
. The commonly seen mechanism
plasmids containing antibiotic resistant genes. The other 
t of cell. This mechanism is 
Occasionally, an enzyme alters antibiotic 
re, it can no longer bind 
 [6]. 
 
. After the 
 [5].  
 is 
-lactamase 
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1.3  Mechanism of Action of Trimethoprim and Trimethoprim Resistance 
 
      Trimethoprim [2,4-diamino-5-(3',4',5'-trimethoxybenzyl) pyrimidine] is a synthetic 
antibacterial agent that belongs to diamino pyromidines class. It   interferes with folic 
acid pathway. Folic acid pathway begins with the formation of dihydropteroic acid from 
para-aminobenzoic acid (PABA) and pteridine by catalytic action of dihydropteroate 
synthetase. Dihydropteroic acid is reduced to dihydrofolic acid under favor of 
dihydrofolate synthetase. Dihydrofolic (DHF) acid is subsequently reduced to 
tetrahydrofolate (THF) with the help of cofactor NADPH by dihydrofolate reductase 
where TMP binds. Therefore, TMP impedes production of tetrahydrofolic acid which is 
crucial precursor of purines, tymidine, methionine, glycine and f-Met-tRNA generation. 
Consequently, DNA, RNA and proteins synthesis is blocked (Figure 3)  [7]. 
 
 
Figure 3: Folic Acid pathway adapted from reference [7]. Trimethoprim inhibits DNA, 
RNA and protein synthesis 
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Chemical composition of Trimethoprim (TMP) allows the drug fit well to the 
active site of dihydrofolate reductase (DHFR) enzyme which is encoded by FolA gene. 
Trimethoprim is structurally similar to folic acid, the natural substrate of DHFR and it 
competes with dihydrofolate for binding DHFR (Figure 4). Trimethoprim is suitable for 
human use since it binds to prokaryotic DHFR with 10000 times more affinity than 
mammalian DHFR [3, 8]. Therefore, TMP selectively binds its target and it is safe and 
efficient folic acid pathway inhibitor. 
 
 
Figure 4: Comparison between structure of Trimethoprim and folic acid. Folic acid is 
the ligand of DHFR whereas Trimethoprim is the competitive inhibitor of DHFR. They 
share similarity colored in orange [9] 
 
TMP was initially used in Proteus septicemia treatment in 1962. After the discovery 
of synergy between sulfonamides, combinations of these drugshave been in clinical use 
against various kind of infections since 1968 in the United States and United Kingdom 
[10, 11]. Latterly, although sulfomides and Trimethoprim combinations have been 
relatively inexpensive to single usage of one, TMP alone was tried to cure urinary tract 
infection in Finland in 1972 due to side effects of sulfonamides. Consequently, TMP 
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was used alone in urinary and respiratory tract infections in several European countries 
and United. Now, TMP is one of the most commonly used antibiotics in the world and 
worldwide utilization of TMP reveals TMP resistance as a significant health problem 
[11]. 
Trimethoprim (TMP) resistance can be either acquired or intrinsic (Figure 6). 
Some organisms are naturally more resistant to TMP .Cell wall and membrane 
impermeability and together with the efflux pumps are main reasons of natural 
resistance to TMP.  For instances, pseudomonas aeruginosa and other pseudomonas 
types are intrinsically invulnerable to TMP because they posses robust cell wall and  
mexABoprM drug efflux system [11]. Furthermore, gram negative bacteria tend to 
be more resistant to several antibiotics than gram positive bacteria due to cell 
membrane structure differences. Although gram positive bacteria has thicker 
peptidoglican layer than gram negative, additional outer lipid membrane of gram 
negative bacteria provides protection from drug penetration. Other intrinsic 
resistance may be originated from having insensitive DHFR against TMP as TMP is 
specifically designed to inhibit bacterial DHFR. Mammalian DHFR has 
approximately 30% similarity with bacterial DHFR (Figure 5). Therefore, they are 
intrinsically resistant TMP.  Bacillus Anthracis and Lactococcus lactis have also 
insensitive DHFR and they are innately resistant to TMP [12, 13]. The last intrinsic 
resistance mechanism is thymidylate bypass. It is very common in folate autotrophic 
species such as Leishmania, a parasitic protozoan. These microorganisms have a 
novel pteridine reductase enzyme which can reduce folate and unconjugated 
pteridines. Hence, DHFR inhibition by TMP cannot affect Leishmania species [14]. 
 
Figure 5: Protein blast of human and bacterial (MG1655 E.coli) DHFR. They share 
28% identities. 
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     Acquired resistance may occur due to production of insensitive DHFR protein by 
acquisition of plasmid from outside or resistant folA gene cassette can be found in 
transposable elements of microorganisms. In nature, there are approximately twenty 
different transferable element such as transposons, plasmids and integrons containing 
resistant folA gene [7]. Such DHFR variants are generally much more inefficient 
than normal enzyme. Most of them have sacrificed electrostatic or conformational 
components for sake of gaining resistance to TMP [15].  Especially, horizontal gene 
transfer of DHFRI and DHFRII variant provides nearly 1000 times MIC (minimum 
inhibitory concentration) value [10]. In addition to those mechanisms, TMP 
resistance may be acquired by spontaneous mutation or gene amplification under 
selective condition. These mutations may be either on efflux pumps so that drugs 
would be expelled before it reaches target or on its actual target DHFR.  Promoter or 
ribosome binding site (Shine Dalgarno sequence) mutations in target or multi drug 
efflux pumps genes have regulatory role in transcription and translation. This causes 
overproduction of intracellular DHFR or efflux pumps expression on surface of 
membrane.  Increased expression of DHFR or multidrug efflux pumps leads to high 
levels of resistance against trimethoprim (Figure 6).                                                                                                
 
Figure 6: Trimethoprim Resistance Mechanism is divided in to two parts: acquired 
and intrinsic. 
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1.4 Structure of Dihydrofolate reductase 
 
Folic acid pathway inhibitors have been used for a long time in both prokaryotes 
and eukaryotes.  Since folic acid pathway is very essential for cells, DHFR is 
targeted by anti malarial agent pyrilmethamine, trimethoprim and as well as 
anticancer drug methotrxate. Long term usage of all these drugs reveals DHFR 
dependent resistance [16]. 
 
 
Figure 7: 3D structure of dihydrofolate reductase (DHFR) complexed with 
dihydrofolic acid (folate) and cofactor NADPH .Enzyme active site is located 
between loop I (met20 loop), α helix B and β sheets a, e, b. 
α helices are represented with upper case letter and β sheets are represented with 
lower case letter [17, 18]. DHFR is composed of eight β sheets (a, b, c, d, e, f, g, h) 
and four α helices (B, C, D, F) 
 
 
 To be familiar with DHFR dependent resistance, structural understanding of 
DHFR is critical. DHFR is ubiquitously found in all prokaryotes and eukaryotes; 
however, there is a great deal of sequence diversity in DHFR while conserving some 
regions on the protein structure that are vital for enzymatic activity and protein 
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stability. For example, all variants of DHFR contain four α helices: two  α  helices 
for substrate binding and two α  helices for  coenzyme binding and also Loop 1 and 
cis peptide bond between two lysine  are common structures.( Loop1 is situated 
between  β sheet A and α helix B and cis peptide bond is located between  β sheet e  
and α helix F shown in figure 7 ). In DHFR catalysis, 2 processes are mainly 
important. These are protonation of substrate and transfer of hydrate ion. The 
aspartic acid (D) residue at position 27 (position 30 in human DHFR) in e. coli is 
responsible in protonation of substrate  dihydrofolic acid and also determines ligand 
specificity [17, 19]. In hydrate transfer, Methionine residue at position 20 in e. coli 
provide electrostatic stabilization [19]. In order to analyze which residues are vital, 
several mutagenesis studies have been completed and Ala9, Asp27, Leu28, Phe31, 
Arg44, His45, Thr46, Leu54, Tyr100, Thr113, Gly121 and Asp122 are shown to 
have huge impact catalytic cycle [20]. These residues are also conserved in 
evolutionary constraint according to detailed SCA analysis of DHFR gene. SCA 
(Statistical Coupling Analysis) is method based on Multiple Sequence Alignment 
(MSA) to reveal long range evolution record. All proteins found in different 
organism evolve from ancestral origin and most of residues evolve independently. 
However small proportion of residues evolves together and the network of 
coevolving residues called sector. Sectors are generally related to tertiary structure of 
protein. Frequency of reiteration of residues in distinct organism displays importance 
of residue for protein functioning [21]. 
  In previous SCA of e.coli DHFR, residues 15, 21, 27, 28, 31, 32, 35, 37, 42, 44, 
51, 54, 55, 57, 59, 63, 77, 81, 94, 113, 121, 125, 133 are determined on sector based 
on p=0,005 probability density cutoff and 3, 11, 13, 15, 21, 22, 27, 28, 31, 32, 35, 37, 
39, 40, 42, 44, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 63, 64, 77, 81, 90, 94, 
100,111, 113, 121, 122, 125, 126, 133, 153 are coevolved DHFR residues based on 
p=0,010 probability density cutoff according to student's t distribution. They 
comprise 14% and 25% of DHFR, respectively  [21]. These residues are thought to 
be hot spots in allosteric control and enzymatic function of DHFR and they should be 
the most affected residues during drug selection. 
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1.5 Morbidostat 
 
 
Figure 8: Morbidostat working principle. X axis shows OD and y axis shows time in 
hours. Each cycle dures ∆t time. Drug or medium addition is decided according OD 
value after ∆t time. Green arrows correspond to media dilution and red arrows 
represent drug injection. Drug is added only if OD>0.15 and ∆OD>0. 
 
Evolution acts on an organism by obtaining continuous adaptive mutations in 
protein sequences. These adaptive mutations are necessary for fitness of the 
organism to the environment and determine population dynamics [22]. In order to 
understand population dynamics and evolution of organism, computer controlled 
selection device "morbidostat" is built. Bacteria cultures growth is monitored over 
time in morbidostat. It enables to keep experimental condition under controlled 
selective pressure by using controlled algorithm. In Morbidostat, The optical 
densities of cultures are recorded in fixed time period (∆t). Growth rate (∆V/V) is 
calculated and device decides to add fresh media or drug. Bacterial growth is 
controlled with dilution and drug inhibition. Whenever the OD of culture is equal or 
exceeds ODthr (OD threshold) or growth rate surpasses dilution rate, drug is added 
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in predetermined dilution time (Figure 8). So, drug concentration is arranged to let 
bacterial population to expose to fixed growth of inhibition. Therefore, more 
reproducible and also resistant bacteria population may be selected among other 
parallel population [23]. 
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2. AIM OF THE STUDY 
 
 Dihydrofolate reductase (DHFR) enzyme has been a target for many drugs since 
it is a fundamental precursor of purines biosynthesis, thymidylate and some amino 
acids. Trimethoprim is the one of these drugs that targets bacterial DHFR and its 
long-term and widespread usage reveals resistance. Although there are various 
mechanism, accumulation of spontaneous mutation in target is expected and 
inevitable scenario. However, there is little knowledge about preference of position, 
fitness, order or nature of spontaneous mutation. Selection of advantageous 
spontaneous mutation having higher fitness is the origin of resistance.  
 In the first part of this study, we aimed analyze the origin of resistance by 
shedding light on mutational choice. Finding advantageous mutation types, their 
compatibility with each other and in what order they were accumulated might 
provide an answer for defeating TMP resistance. Secondly, we purposed to gain 
more insight about dynamics of population and final destination of mutational choice 
against different selection types. For that reason, we arranged our experimental 
condition to let bacteria populations grow only if their fitness was above a certain 
threshold and we used mild dilution for 6 cultures and strong TMP dilution for 7 
cultures to generate distinct selection environment. Finally, we aimed to establish a 
connection about preferences of mutation by researching network of evolutionary 
coevolved residues called sectors with Statistical Coupling Analysis. So we asked 
that sectors were more likely to be hit against selective pressure. Consequently, with 
this study,   the next step of mutational choice may be predicted. New synthetic TMP 
analogs may be designed for a particular mutation types in future.   
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3. MATERIALS & METHODS 
3.1. MATERIALS 
3.1.1 Chemicals & Media Components 
 
 
Chemicals for Media 
Components 
 
 
Supplier Company 
 
Agar-Agar 
 
Merck, Germany 
 
DMSO 
 
Biochem, Germany 
 
Choloramphenicol 
 
Sigma, Germany 
 
Ethanol 
 
Merck, Germany 
 
Glucose 
 
Sigma, Germany 
 
LB 
 
Merck, Germany 
 
Magnesium Sulfate 
(MW: 246,48) 
 
Sigma, Germany 
 
M9 Minimal Salts 5X 
 
Sigma, Germany 
 
Protein Hydrolysate 
Amicase 
 
Fluka, Germany 
 
Calcium chloride 
(MW: 147,02) 
 
Applichem, Germany 
 
Trimethoprim 
 
Sigma,Germany 
 
Table 1: Chemicals that are used in Media 
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3.1.2 Antibacterial Agents  
Chloramphenicol and Trimethoprim stock solutions were prepared as 50 mg/ml 
dissolved in 100% ethanol and DMSO respectively.  Solutions were stored at -200C 
3.1.3 Growth Media 
M9 minimal salt solution (1X, autoclave sterilized) was supplemented with 4% glucose 
(autoclave sterilized), 0.2% amicase and MgSo4 and CaCl2 was added to solution to 
have final concentration 2mM, 100uM respectively.  Solution was sterilized with 
corning cellulose Acetate membrane 0.22 micron bottle top filters and stored at room 
temperature. Chloramphenicol was added to media to obtain last concentration as 
25ug/ml before use in experiment 
 
LB-Agar 20ml per plate was used as solid medium for bacteria growth 
3.1.4 Bacteria Strains 
AttP21-PR-Mcherry Chlaramphenicol resistant MG1655 strains from Tobias 
Bergmiller, IST were used in whole experiment. 
3.1.5 Software 
Matlab program was used in morbidostat part of experiments and clc main workbench 
was used to analyze DHFR sequencing result  
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Equipment Company 
Autoclave Priorclave, UK 
 
Balance Schimadzu, TW423LV, Japan 
Sartorius, BP610, Germany 
Distilled Water Millipore, Elix S, France 
Shaker Incubator  New Brunswick Sci., Innova 44, USA 
 
Spectrophotometer Amersham Biosciences, UK 
Incubator  Memmert, Modell 300, Germany 
Laminar Flow Heraeus, Germany 
Microliter Pipettes Gilson, Pipetman, France 
Microscope Olympus, CK40, Japan 
Olympus, CH20, Japan 
Olympus, IX70, Japan 
Plate Reader TECAN Infinite F200 pro 
TECAN Infinite M200 pro 
Pinner V&P Scientific,USA 
Plate Shaker Incubator Heidolph, Germany 
Deep Freeze -20 Regal, Turkey 
Deep Freeze -80 New Brunswick Sci.,U410,USA 
Refrigerator  +4 Regal, Turkey 
Vortex VWR,USA 
 
Table 2:  Equipments are used in this study. 
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3.2 METHODS 
3.2.1 Morbidostat 
Initially, 100 ul frozen wt isogenic bacteria cultures were added to 13 sterile culture 
tubes containing 12 ml M9 minimal media having 25ug/ml CHL. Before tubes were 
placed to tube holder of incubator, drug A, B and media flow and pumps were checked 
and matlab code was started. Neither media nor drugs were injected to tubes in order to 
let bacteria adapt to the environment in first hours. When the OD of cultures surpassed 
0.03, injection started and continued 1 min for strong selection and 30 min for mild 
selection in every 18 min. At the end of this cycle waste pumps were functioned to keep 
all cultures at same volume and for avoidance of overflow. Each pump was set to have 
flow rate as 1ml/min. 
 
Figure 9: Morbidostat experiment working mechanism.  Drug A is added if OD is 
between 0.15 and 0.3  and culture has positive trend in growth. Drug B is added if OD is 
greater than 0.3 and concentration in tube is higher than 60% of drug A. Otherwise 
media is added. 
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 According to growth rate of cultures, computer algorithm determined whether 
Drug A or B or fresh media injection. If OD was smaller than 0.15, media was added. If 
it was between 0.15-0.3 or growth rate was exceeding the dilution rate, Drug A was 
added. If it was greater than 0.3 or the concentration of drug in culture tubes was greater 
than 60% of drug A, drug B was added (Figure 9). In addition, Pumps of morbidostat 
were set for mild and strong selection. Drugs were added during 30 second for mildly 
diluted cultures (culture 1-2-3-4-6-7) and 60 second for strongly diluted cultures. 
Therefore, dilution rates were arranged to a certain thresholds which were 0.3 hour-1 and 
0.6 hour-1 in mildly and strongly diluted cultures respectively. In both systems, bacterial 
growth was restricted but mild dilution system was more tolerable than strong dilution, 
which provides survival of more bacteria population. (Figure 10) After 20-24h, cultures 
were frozen by using 15% glycerol at -800C and following experiment was started from 
frozen samples. 
The concentration of drug bottle used in experiments is shown in following table: 
days drug A drug B 
day 1 10ug/ml 50ug/ml 
day 2 10ug/ml 50ug/ml 
day 3 10ug/ml 50ug/ml 
day 4 10ug/ml 50ug/ml 
day 5 10ug/ml 50ug/ml 
day 6 10ug/ml 50ug/ml 
day 7 10ug/ml 50ug/ml 
day 8 50ug/ml 250ug/ml 
day 9 50ug/ml 250ug/ml 
day 10 50ug/ml 250ug/ml 
day 11 50ug/ml 250ug/ml 
day 12 250ug/ml 1250ug/ml 
day 13 250ug/ml 1250ug/ml 
day 14 250ug/ml 1250ug/ml 
day 15 250ug/ml 1250ug/ml 
day 16 250ug/ml 1250ug/ml 
day 17 250ug/ml 2000ug/ml 
day 18 250ug/ml 2000ug/ml 
day 19 250ug/ml 2000ug/ml 
day 20 400ug/ml 2000ug/ml 
day 21 400ug/ml 2000ug/ml 
day 22 400ug/ml 2000ug/ml 
day 23 400ug/ml 2000ug/ml 
day 24 1000ug/ml 50ug/ml 
day 25 1000ug/ml 50ug/ml 
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day 26 1000ug/ml 50ug/ml 
day 27 1000ug/ml 50ug/ml 
   
 
Table 3: Drug A and B concentration in each days of experiment. Drug B is generally 5 
fold of concentration of drug A 
 
 
 
 
Figure 10: Comparison of strong and mild dilution in morbidostat. Dilution rate is more 
restricted in strongly diluted cultures than mildly diluted cultures. Colors and sizes 
represent that population is very mixed. Arrows show three imaginary conditions which 
are same in each rectangle. Red colored (mutant) bacterium in first arrow has higher 
reproducibility than in third arrow which also has higher reproducibility than second 
arrow. Two Bacteria populations having less fitness than other are eliminated from 
cultures in strongly dilution case while one bacteria population is eliminated from 
culture in mild dilution case. 
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3.2.2 Measurement of Growth Rate 
96 well plates containing 150ul M9 minimal media (25ug/ml CHL) was prepared 
and then bacteria were seeded with pinner from master plate (appendix a). They have 
grown at 30C with shaking and OD measurement was done in every 15 minutes with 
TECAN for 24 hours. Growth rate is calculated with ln (OD2/OD1) / t2-t1 formula 
according to exponential phase of each day of population. 
3.2.3 Determination of Minimal Inhibitory Concentration (MIC) 
MIC values of each day of each culture were determined. 18 different concentration 
of TMP was tested (3000, 2500, 2000, 1500, 1000, 500, 250, 125, 62.5, 32, 16, 8, 4, 2, 
1, 0.5, 0.25 and 0 ug/ml). 96 well plates comprising 150 ul M9 minimal media with 
25ug/ml CHL and different concentration TMP solutions were prepared. Bacteria were 
added with pinner from master plates (appendix a). They have grown at 30C with 
shaking for 24 hours. OD of each well was measure with the help of TECAN. The result 
was analyzed with Matlab code  
3.2.4 Single Colony Selection and Sample Preparation for Sequencing 
Mix population was streaked into LB agar from daily frozen samples of 
morbidostat. They were grown at 37C over night. Then single colonies were chosen 
randomly. They were grown in M9 minimal media with 25ug/ml CHL overnight and 
frozen with 15% glycerol.  
1ml Agar stabs were prepared for sample preparation and 20 ul bacteria from frozen 
single cells were seeded on to agar stab and kept in +4.  
3.2.5 Sequencing 
SNP Discovery/Mutation Discovery sequencing was performed for   bacterial 
samples. FolA gene of E. coli (K12 MG1655) region was sequenced by using following 
primers: 
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Toprak28-5 GGGAACCGAAGAAGGTAAACA  
Toprak28-3 GCGTCTTAAACACAGCCTGAT 
 
Sequencing primers for SNP located in 34 nucleotides upstream of folA gene 
designed specifically to target position from 50136 to 50535 of e.coli genome. 
 
3.2.6 Sequencing Analysis 
 
Pair wise sequence alignment were done my using mclab tools and mutations were 
analyzed by using clc main workbench 
3.2.7 Statistical Coupling analysis (SCA) 
SCA analysis was performed with MSA of 4166 sequence by using promals 3D 
software.  RMDS is root mean square deviation and calculated with following formula: 
RMDS=∑ ()	

    where K is Kimberly Reynold's alignment and Y is our 
alignment. 
3.2.8 f  Statistic Calculation 
FRS was calculated with following formula: 
FRS=(HR-HS)/HR   where   HR is regional heterozygosity and separately calculated for 
two regions which are strong and mild selections and HS is subpopulation 
heterozygosity and calculated for each day with following formula: 
HS=1-∏ 
   P is frequency and n is number of sub clones. Detailed calculation is 
shown in figure 9. 
 
  
Figure 11: Calculation method of Heterozygosity of subpopulation. Green circles 
represent wild type and 
3.2.9 Mutation Assessor 
FI scores were calculated by using program that are found in website 
(mutationassessor.org) 
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red stars represent mutant genotypes.
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4. RESULTS 
 
In our experiment, we evolved 13 Chloramphenicol resistant Mcherry MG1655 
E. coli strains by using morbidostat. We carried out experiment during 23 days (504 
hour). We tried two different selective pressures by setting trimethoprim dilution strong 
and mild. First six cultures were determined to be exposed to mild dilution and other 
seven were prescribed as strong selection. We took daily stock from each day of each 
culture tubes. After experiment was completed, we sent samples to sequencing from day 
1, 4, 7, 10, 13, 16, 19, 23. If we noticed any complexity to understand mutation order, 
we sent samples from other days as well. Thereafter, we continued to experiment four 
days more in order to analyze whether cultures gain another mutation or not.  
 
4.1 Final Genotypes of cultures 
 
Although there were similarities between mutation positions, we observed nine 
different genotypes out of thirteen cultures. We detected that some mutations have not 
been involved in some mutational combinations due to epistatis.  For instances, A26T 
was not observed with D27E in any genotypes. This mutation was mostly placed after 
L28R or W30 residue mutations. Additionally, D27E was always accumulated after or 
before F153 residue mutations.  
Promoter mutations also accumulated next mutation according to some 
preference. For instance, g-31 was observed in only three genotypes and acquired L28R 
and A26T as final genotype (Figure 12).  
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Figure 12: Final genotypes of cultures evolved under mild and strong dilution. Promoter 
mutations are found in the middle of circles and symbolized by gradient of grey colors. 
 
 
4.2 Mutation Trajectories 
 
 
 
Figure 13: Mutation trajectories of culture 1. Grey, magenta and cyan circle correspond 
to g-31a, L28R and A26T, respectively. White diamond represents c-35t mutation at 
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day 13. ¼ of population have both g-31a and c-35t promoter mutation. The order of 
mutation is g-31aL28RA26T 
 The first mutation acquisition of culture 1 is promoter mutation at position -31 
which is g to a transition. Second mutation is L28R which is Leucine (Leu) to Arginine 
(Arg) amino acid transition at 28th amino acid as a result of t →a change in 83rd 
nucleotide position at day 7.  A26T Alaline (Ala) to Threonine (Thr) change is the third 
and last SNP that we observed at day 19. The possessions of these three SNPs are 
conserved until day 27 of the experiment.  The sequencing result of culture 1 is highly 
ordered except at the day 13. One single colony has 2 promoters: g-31a and c-35t 
mutation with A26T at this day but this combination is not observable at day 19 (Figure 
13). 
 
 
Figure 14: Mutation trajectories of culture 2. Black circle represents D27E.  g-9a is 
shown with dark grey circle located in the center of the cylinder surface. Orange 
diamond and orange circle correspond to F153V and F153S, respectively. Mutation 
acquisition orders are D27Eg-9aF153V and D27Eg-9aF153S 
 
 In the case of culture 2, the first mutation suprisingly is not a promoter mutation. 
Negatively charge Aspartic acid (D) residue at 27th residue is firstly changed in to again 
negatively charged Glutamic acid (E) because of tg transition at 81st nucleotide, and 
secondly, g-9a promoter mutation is accumulated approximately at day 7. Finally, ta 
transition in 456th nucleotide of DHFR results Phenyalaline (Phe) to valine (Val) 
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change in 153rd residue at day 10. Although all sequencing result of day 11 shows that 
100% of populations have F153V, the percentage diminishes to half and at day 12 
because of F153S accumulation (t→c in 457th position). F153S is over dominated the 
population. D27E, g-9a and F153S SNPs are rested until the final day of experiment. 
Sequencing result of culture 2 clearly showed that F153S is capable of eliminating 
F153V (Figure14).  
 
Figure 15: Mutation trajectories of culture 3. Dark grey circle located on the center is g-
9a promoter mutation. Green, orange and black circle represent W30C, F153S, D27E, 
respectively.Mutation order is g-9aW30C<F153SD27E in culture 3 
 
Culture 3 is again initiated with promoter mutation (g  t) at 9 nucleotides 
downstream of ribosome binding site of fol A gene. At day 4, W30C is accumulated in 
¼ of culture population and ratio increases to ½ of population at day 9. However, newly 
acquisition of F153S starts to compete with W30C with same ratio. We can basically 
differentiate of which mutation’s fitness is stronger by glancing at sequencing results of 
day 10 since ¾ of population now turns to g-9a + F153S and rest of the population is g-
9a+W30C and at day 11. Complete dominance of F153S can be easily observed. New 
mutation D27E occurs at day 12 with ¾ ratios. This combination does not change until 
the final day of experiment. Similar to F153V, W30C has lower fitness effect on 
population than F153S (Figure 15) 
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Figure 16: Mutational trajectories of culture 4. Dark grey and light grey circle found in 
the middle of cylinder surface are promoter mutation g-9a and c-35t, respectively. 
Orange diamond signifies F153V whereas black, brown and magenta circles correspond 
to D27E, M20I and L28R SNPs. g-9a D27E F153V M20I<L28R is sequential 
acquisition of mutation in culture 4 
  
Sequencing result of Culture 4 on day 4 proves that mutation accumulation begins 
repeatedly with promoter mutation g-9a with 100% but other promoter mutation c-35t is 
observed in 25% of culture. Wilt type bacteria population increases DHFR expression 
by two promoter mutation. On day 6, 100% of population possesses g-9a +D27E 
mutation. After, F153V is added and whole population possesses g-9a, D27E and 
F153V on day 7. On day 11, new mutation M20I arises in ¼ of cultures and increases to 
½ on day 12. The rest of the population on these days does not acquire any mutation. 
While they are competing with each other, g-9a, D27E and F153V population gains 
L28R mutation on day 13 and expel population having g-9a,D27E, F153V and M20I. 
By analyzing this competition, we could result M20I fitness effect is lower than L28R if 
population contains g-9a, D27E and F153V as background mutations. (Figure 16) 
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Figure 17: Mutation trajectories of culture 6. Dark grey, green, purple, navy blue, cyan 
circle correspond to c-35t, W30C,c+34t, I94L, A26T, respectively 
 
 Culture 6 has five sequential mutation accumulations.  Initial SNPs is a promoter 
mutation c→t in 35 nucleotides downstream of Shine Dalgarno sequence of folA. 
Second mutation is W30R which is detected in 100% of population on day 7. Third 
mutation is interestingly not found in coding region, instead is located 34 base pairs 
upstream of folA gene. +34 position was repeatedly sequenced with other primer pair in 
order to be sure of its existence. Acquisition of c+34g mutation is initiated on day 8 
with ¼ ratios but whole culture population contains this mutation on day 10 . Fourth 
mutation is isoleucine to leucine change at 94th residue is acquired in same day. The 
final fifth mutation is A26T. c-35t, W30R, c+34, I94L and A26T combination pursue 
their existence until 27th  day of experiment. Mutation acquisition order of this culture is 
very clear and ordered. (Figure 17) 
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Figure 18: Mutation trajectories of culture 7. Light grey circle represents c-35t promoter 
mutation. Black, magenta, cyan circles correspond to D27E, L28R, A26T, respectively. 
Green diamond signifies W30G. 
 
c-35t promoter mutation is first arising mutation of culture 7. On day 6, W30G 
mutation is added on c-35t and occupies 100% of population. However, on day 7, 
population is divided into 2 genotypes. 50% of population carries c-35t+W30C and 
others have c-35t+D27E. On day 8, 5/8 of population has c-35t+D27E and 3/8 carries c-
35t+W30C. We could make an inference that D27E is better mutation than W30C in the 
case of reproducibility and fitness only if their background is same. On day 9, culture 7 
population are divided in 3 genotypes. 1/8 has still c-35t+D27E and 1/8 has c-
35t+D27E+W30C. These two combinations are washed out in later days. The rest of 
population carries c-35t+W30C+A26T which is occupied by 100% of population at day 
10. L28R is lastly accumulated on c-35t+W30C+ A26T. (Figure 18) 
 
Figure 19: Mutation trajectories of culture 8. Light grey, red, magenta and cyan circles 
correspond to g-31a, P21Q, L28R and A26T, respectively. The orders of mutation 
acquisitions are g-31ap21L and g-31aL28R A26T 
 
 After the g-31a promoter mutation acquisition on day 4 and 5 of culture 8, 50% 
of population P21Q accumulates on g-31a. Nonetheless, L28R prevails over P21Q and 
A26T is accrued on g-31a+L28R. This composition lasts to day 27. (Figure 19) 
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Figure 20: Mutation trajectories of culture 9. Light grey, black, magenta and cyan 
circles represent c-35t, D27E, L28R and A26T, respectively. Orange diamond, green 
diamond and orange circle correspond to F153V, W30G and F153S, respectively. 
 
Dynamic of population is very complex in culture 9.  First mutation c-35t is 
observed on day 4 of experiment. On day 6, 3/8 of population gains W30G, 2/8 of 
population acquires D27E and 1/8 of population accumulates F153S on promoter 
mutation. On day 7, c-35t+W30G and c-35t+F153S populations share same ratio which 
is 3/8. The rest of bacteria culture has c-35t+D27E. On day 8, c-35t+F153S mutation is 
found in ½ of population, 3/8 of population consist of c-35t+W30G and 1/8 of 
population contains c-35t+D27E which is excluded from culture in later days. On day 
10, 7/8 and 1/8 of culture carries c-35t+F153S and c-35t+W30G, correspondingly. 
Nevertheless, c-35t+W30G group makes an attack to c-35t+F153S by acquiring A26T 
and dominates culture with 6/8 ratio. c-35t+F153S group  attacks again by starting 
D27E accumulation with 1/8 ratio on day 11 and is predominated with 6/8 ratio on day 
12. c-35t+W30G+A26T is started to be eliminated from culture on day 12-13. However, 
survival of c-35t+F153S+D27E group is disrupted by L28R mutation. Competition 
between c-35t+F153S+D27E group and c-35t+F153S+L28R group maintains during 
next 4 days. Finally, c-35t+F153S+L28R group wins. From this competition, we could 
make three assumptions: (1) F153S>W30G>D27E if strains have c-35t promoter 
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mutation background (2) L28R>D27E if they have c-35t + F153S background (3) 
F153S+D27E couple is stronger than W30G+A26T couple. (Figure 20) 
 
 
Figure 21: Mutation trajectories of culture 10. Dark grey and light grey colors 
correspond to promoter mutation g-9a and c-35t, respectively, Black and Magenta 
colored circles represent D27E and L28R mutations. Orange diamond signifies F153V 
and brown circle represents F153L. 
 Culture 10 commences with g-9a promoter mutation on day 3 but percentage is 
dropped into 25% on day 4 by dint of c-35t promoter mutation acquisition, which 
proves the c-35t is capable of annihilate g-9a promoter mutation. D27E is acquired on 
day 10 and F153V is acquired on day 13. However, Genotype of population turns into 
c-35t+D27E+F153L+L28R because c-35t+D27E firstly accumulates L28R and then 
F153L on day 15 and this configuration is final destination of culture 10. (Figure 21) 
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Figure 22: Mutation trajectories of culture 11.  Light grey and dark grey circles signify 
promoter mutation g-31a and g-9a, correspondingly. Magenta, Cyan and orange filled 
circles represent L28R, A26T, F153S. The mutation order is g-
9aL28RA26T<F153S 
 
 Culture 11 follows promoter mutation path which consists of ¾  g-9a and ¼  g-
31a on day 4, per contra, ratios of promoter mutation becomes exact opposite on day 6 
proving that the fitness effect of g-9a is superior than g-31a. However their conflict 
continues with addition of new mutations. g-31a acquires P21L on day 7 with the ratio 
1/3  whereas  g-9a is accumulates L28R which dominates the whole culture on day 8. 
Laterly, g-9a+L28R population  is divided into 2 with gaining F153S with 1/8 ratio and 
A26T with 7/8 ratio on day 13. These two populations fight each other to survive during 
day 13-18. On day 19, g-31a+L28R+F153S finally overwhelms with g-
31a+L28R+A26T group. However, we may result that   the fitness effect of F153S is 
higher than A26T but very close because scrambling time dures very long and the 
winner is exactly opposite for some days. (Figure 22) 
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Figure 23: Mutation trajectories of culture 13. Light grey, green, magenta, cyan and 
yellow filled circles correspond respectively to c-35t promoter mutation, W30C, L28R, 
A26T, R98P. 
 
 As usual, promoter mutation comes first in culture 13. W30C is secondly gained 
c-35t on day 7. Nevertheless, four different genotypes are observed on day 11.  Two of 
which are population that get hold of new mutation on c-35t+ W30C. c-35t +W30C + 
D27E occupies 1/8 of population whereas c-35t+ W30C+A26T is included in half of 
population. 1/8 of culture does not accumulate any new mutation and the other 1/8 of 
population gains L28R mutation right on the promoter mutation on day 11. On day 12, 
most of the population becomes c-35t+ W30C+A26T. R98P mutation is accumulated by 
population on day 15 and maintained until the last day experiment.  The mutation 
acquisition orders are determined as c-35t→W30C → D27E →R98P and c-35t→W30C 
→  A26T →R98P. (Figure 23) 
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Figure 24:Mutation trajectories of culture 14. Light grey and grey circles correspond to 
c-35t and g-31a. D27E is shown with black circle. Dark green and light green filled 
circles represent W30C and W30R. A26T and L28R are shown respectively with 
Magenta and cyan circles. 
 
A mutation trajectory of culture 14 begins with c-35t promoter mutation. 1/8 of 
population accumulates D27E and other 1/8 of population gains W30C on fifth day of 
experiment. c-35t+D27E is not observed once again. 3/8 of population has W30R and 
the rest of population has W30C on the day 6. However, on day 7, undetectable 
promoter mutation g-31a acquires L28R and this group spans 5/8 of population by 
beating W30R and W30C. By looking sequencing result, we can compare the fitness 
effect of W30C and W30R because W30C is directly eliminated from population but 
W30R fights against g-31a+L28R. g-31a+L28R fails on day 10. g-31a+L28R gains 
A26T on day 13 and genotype of population becomes g-31a+L28R+A26T (Figure 24) 
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Figure 25: Mutation trajectories of culture 15. Dark grey and light grey symbolize 
promoter mutation c-15gand c-35t respectively. Black, Orange, magenta and red circles 
correspond to D27E, F153S, L28R and P21Q, correspondingly. 
 c-15g novel promoter mutation is firstly observed in culture 15 on day 4. 
However, all genotypes of population are P21Q at day 5 but it is eliminated from 
cultures.   c-35t is occupied by half of the population on day 7 and defeats c-15g on day 
8. Population then acquires P21Q with 1/4 ratio on c-35t at day 9 and occupies half of 
the population on day 10. c-35t + P21Q group competes with c-35+F153S on day 10 
and fails.  c-35+F153S accumulates D27E on day 13 with 5/8 ratio, the rest of culture 
posess c-35t+L28R .Laterly, c-35t+L28R gains F153S on day 14 and it is eliminated on 
day 15 but this group reattacts during day 16-23 and defeats c-35t+F153S+D27E.  As a 
result of culture 15 trajectories, L28R has higher fitness than D27E as observed in 
culture 9 (Figure 25) 
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4.3 Minimum Inhibitory Concentration Measurement  
After completion of morbidostat experiment, minimum inhibitory concentrations 
(MIC) of daily stocked cultures were measured. Both cultures evolved under mild and 
strong cultures gained similar level of trimethoprim resistance in stepwise manner 
(Figure 26, Figure 27). All MIC results are shown in appendix B.  
 
Figure 26: Minimum inhibitory concentration of culture 1 as an example of mildly 
evolved culture 
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Figure 27: Minimum inhibitory concentration of culture 9 as an example of strongly 
evolved culture 
4.4 Growth Rate Measurement  
After the morbidostat experiment completed, growth rate of daily population of 
each culture were measured with TECAN and calculated according to exponential 
phases. According to growth rate measurement, both growth rates of strongly diluted 
culture and mildly diluted samples were suited to predetermined dilution factors. (0.3 
for mild and 0,6 for strong dilution). Neither of cultures was dropped under the dilution 
factors (Figure 24-25). 
Furthermore, nearly growth rate of all cultures decreased after first mutation 
accumulation. Since almost all cultures firstly accumulated promoter mutation, we 
could conclude that expression level change of DHFR have been some costs for 
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bacteria. We did not make any comments on other drop or increment in growth rate 
because of clonal interference.   
 
Figure 28: Growth Rate of mild selection cultures versus days. 
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Figure 29: Growth Rate of strong selection cultures versus days. 
4.5 Statistical Coupling Analysis  
 Statistical coupling analysis is bioinformatics technique based on multiple 
sequence alignment used to characterize to evolutionary constrained amino acid in 
protein family. More specifically, this method quantifies how much amino acid 
distribution at one position is altered when the amino acid distribution of at another 
position is changed. If distribution is different from mean of distribution which is the 
expected amino acids distribution (generally, 20 different amino acids are expected to 
  
be found at same frequency), some degree of conservation exists and amino acids are 
coupled, which is called sectors. Global 
weighted correlation matrix
multiple sequence alignment consisting
statistical coupling matrix
function of entropy (D). If D value 
and it is shown in matrix with red color (Figure 30). Number of conserved residue of 
DHFR and conservation scores of each position are shown in figure 31 and 32 
respectively. Pairwise conservation scores were calculated and sectors were a
with p=0.0135-0.0225 cutoff. 
35, 37, 39, 42, 44, 49, 53, 54, 55, 57, 59, 71, 81, 90, 94, 107, 113, 121, 122, 125, 126, 
133, 153, 158 were found in sector region. 
our SCA result with SCA of Ranganthan Lab
(Figure 33).  
Figure 30: The Statistical Coupling Matrix: a weighted correlation matrix consisting of 
4166 sequence of DHFR variants. Blue color 
color signifies more conserved residues.
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analyses of coupled residues are analyzed in a 
. In order to characterize residues of DHFR, We performed 
 of 4166 sequence of DHFR
. Position specific conservation scores were 
is greater than one, residue was highly conserved 
Residues 7, 11, 14, 15, 18, 21, 22, 23, 24, 25, 27, 31, 32, 
To test our consistency, we also 
. We found that they are highly consistent 
represents less conserved where
 
 variants in 
calculated as 
nalyzed 
compared 
 
as red 
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Figure 31: Number of conserved residues in DHFR versus  conservation scores. Scores 
that are higher than 1 is accepted as conserved residue. 
 
Figure 32: Conservation Score of each residue of DHFR. DHFR contains 156 amino 
acids. 
  
Figure 33: Previous MSA alignment 
Ranganathan Lab, Texas, USA) 
sequences whereas we used 4166 sequence of DHFR 
residues. RMDS is root mean square deviation and correspond to magnitude of variation 
between two results.  Residue numbers are symbolized with gradient color from orange 
In addition, we compared detected SNPs with
nearly all mutants are inside sector region. Culture 1 is 
2, 4, 10 firstly accumulates D27
coding mutation at P21 and 
together. Culture 6 and 13 firstly acquire W30 mutation. C
and D27. Culture 9 acquires D27, F153 and W30
L28 as first coding mutation. 
F153 are situated in sectors only exception with W30, 
mutational choice of culture are almost in sector regio
are also found in sectors 
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(alignment of Kimberly Reynolds from 
versus our alignment. Kimberly Reynolds used 418 
in MSA to find SCA score of 
to navy blue. 
 our SCA scores and we found that 
firstly hit in L28 residue. 
. Culture 8 and 11 hit P21 and L28. Culture 15 has
F153 residues. Culture 3 accumulates W30
ulture 7 accumulates W30 
. Culture 14 acquires W30, D27 and 
Since all first coding mutation such as P21,
we can conclude that fi
ns. Generally, second mutations 
according to our analysis but we cannot generalize them 
 
Culture 
 first 
 and F153 
 D27, L28, 
rst 
43 
 
 
because epistatic interaction between SNPs also effects on preference of second coding 
mutation in bacteria. 
 
Figure 34: Mutated residues located on sector region. All mutated residues are shown in 
3D structure of DHFR. Mutations found in sectors are shown with ball shape. P21, D27, 
L28, I94, F153 are found in sector. If mutation found in sector is preferred as first 
coding mutation, it is labeled with star. 
4.6 Functional Impact Score and Mutation Assessor 
 Microorganism develops new strategies to survive against wide use of drugs and 
the most observable strategy is acquiring of spontaneous mutation. Such mutation-based 
resistance, however, is not only particular to microorganisms. Cancerous cells may also 
develop resistance by mutation acquisition against chemotherapy and even the origin of 
the cancer cells is due to an amino acid change resulting to oncogene activation or 
inhibition of tumor suppressor gene. This kind of mechanisms make researchers to find 
out nature of mutations, many new bioinformatics software are newly introduced to 
literature. Mutation Assessor is the one of the software program that calculates mutation 
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impact on proteins function such as stability, protein- protein interactions, catalytic 
activity or protein expression based on FIS (Functional impact score). It is mainly 
developed for cancerous mutation. It uses evolutionary information coming from 
conserved patterns. As in Statistical Coupling Analysis (SCA), FIS uses multiple 
sequence alignments of protein families and sub families to reveal the mystery of 
residues playing important role on protein function and also cancer progression. As a 
result of alignment, conservation score and specificity score is calculated. Conservation 
score is computed based on entropy differences between original residue and variant 
residue by analyzing entire protein family. Entropy differences are high if residue is 
conserved across the protein family. Entropy term reflects the physical and chemical 
effect of residue on protein.   Specificity score is calculated based on conservation in 
sub family, by this way, diversifications are lowered whereas the specificity of residues 
increases the sum of the conservation score and specificity score gives the Functional 
Impact Score (FIS). After the FIS calculation, Validation test is performed by using 
Uniprot database containing 60,041 neutral and disease associated variants. FIS scores 
are differentiated as disease associated or unaffected mutant. As a result, phenotypic 
consequences of polymorphism are detected by this method which is also called 
mutation assessor. [24] 
 Mutation assessor has been mostly utilized to find cancer and disease associated 
mutation. However, we applied this technique to detected DHFR SNPs so as to analyze 
the impact on protein function because DHFR have found in all organisms as an 
essential enzyme and shared approximately 70% similarity with human DHFR. 
Additionally, DHFR enzyme was not completely irrelevant with cancer topic, on the 
contrary, it has been used as a drug target for cancer cells. In our analysis, we detected 
almost all mutants have medium or high impact.  
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Figure 35: Mutation Assessor FI scores of mutant residue. Dark grey region represents 
high impact whereas light grey region corresponds to medium impact mutation. If FI 
score is lower than 2, such mutant has lower effect on protein structure. If score is 
between 2 and 3.5, it is accepted as medium impact and if score is higher than 3.5, 
mutant is highly effective. 
 
 According FIS analysis, P21L has 1.91 FI score and W30R has 0.915 FI score. 
Therefore they have low impact. However, P21L is very close to 2 and we can assume 
that it has medium impact. Besides, P21Q is counted as high impact mutant that has 
4.805 FI score. The other residues that have high impact are L28R and F153S with 
score 3.825 and 4.71, correspondingly (figure 35). Consistently, these two mutations are 
situated on nearly all final destination of cultures together or alone except culture 9 and 
culture 13.  
 FI scores of W30G and W30R are also very high although they are placed in 
medium impact area of graph. F153V, F153L and I94 L are also found in medium 
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impact area with score 2.905, 3.185 and 2, 9 respectively (figure 35).  From that result, 
we can conclude that F153 residue is very important for protein stability or catalytic 
activity and also 6/13 of culture harbor one of F153 variant in their final destiny. M20I, 
A26T, D27E, R98P have also medium impact FI score. They are all found in final 
destination except M20I.  
4.7 F statistic and dynamics of cultures  
F statistic is very helpful to analyze evolutionary process and genetic variation in 
population. Therefore we calculated FRS score of each day of each culture so as to find 
sub population divergence from regional populations. Region corresponds to dilution 
types in our study. By this way, diversity of mildly and strongly diluted cultures may be 
compared. Indeed, Diversity of strongly diluted cultures is higher than the mildly 
diluted cultures. For instance, if we compare HS of culture 2 (mild culture) with culture 
15 (strong culture), two days of culture 2 include diversification whereas culture 15 has 
durable diversity which continues thirteen days. (Figure 36a and 36b) However, if 
whole diversity score is analyzed, there are also some exceptions such as culture 8, 10 
and 14 from strong cultures having low diversification.  (Appendix C) 
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Figure 36a: Heterozygosity of subpopulation of mild selection exemplified by 
culture 2. Day 3 and day 11 of culture 2 comprise dissimilar subpopulations. if Hs=0; 
there is no diversity 
 
Figure 36b: Heterozygosity of subpopulation of strong dilution is exemplified by 
culture 15. Day 4, 5, 6, 7, 9, 13, 16, 17, 18, 19, 20, 21, and 22 of culture 15 comprise 
dissimilar subpopulations. If Hs=0; there are no diversity. 
 
Furthermore, Mean Duration of strongly diluted cultures is 6.42 days and nearly 3 
fold of mildly selected cultures which is 2.66 days.  The standart deviations are 1.21 for 
mildly diluted cultures and 4.5 for strongly diluted cultures.  According to t test that we 
performed p value is 0.036 and it is not statistically significant. Therefore, 
diversification is higher in strongly diluted cultures than mildly diluted cultures. (Figure 
37) 
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Figure 37: Comparison of mean duration of mild and strong selection. Black color 
represents mild selection whereas red color signifies strong selection. Navy blue shows 
standard deviation of calculation 
 
 In addition to FRS Analysis of cultures, figure 32 also shows that mutational 
diversity is higher in strongly diluted population than mildly diluted population 
especially in first coding region mutation. Mild Selection cultures have seven paths in 
first coding mutation however; strong Selection cultures have ten paths for first coding 
region mutation. Therefore, dynamics of cultures is not same within and between 
dilution types.  
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Figure 38: Mutational dynamics of strongly and mildly selected cultures. Middle line 
separates two selection types. Promoter mutations are located in the center of cylinders 
represented with colors light grey, grey and dark grey. Other colors represent different 
coding mutations 
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5. DISCUSSION 
 
 Protein motion, reorientation of domains and sub domains are all related to 
protein function which involves binding and release of cofactor and substrate. Such 
dynamics are mediated by allosteric regulation protein. In DHFR, hinge bending 
motions and active loop movement are primary responsible for substrate and cofactor 
binding and release by determination of active site cleft closure. The active site cleft 
separates DHFR in to two sub domains. These are adenosine binding sub domain and 
major sub domain. Adenosine binding domain is located between residue 38 and 88 
generates binding site for cofactor. Lys 38 and Val88 provide hinge bending motions to 
generate movement of adenosine binding domain for cofactor binding and this 
movement closes the active site cleft. Major sub domain which is also called loop sub 
domain occupies 40-50% of DHFR in nucleotide length. Loop sub domain is also 
divided into 3 parts. These are Met20 loop also called Loop I found between residue 9-
24, FG loop also called Loop II lying between 116 and 132nd residues and GH loop is 
located between residues 142 and 150. Met20 loop is directly related to enzymatic 
activity of DHFR protein whereas FG and GH loops are responsible from stabilizing of 
protein via hydrogen bond interaction with Met20 loop. Met20 loop has 2 
conformations according to substrate binding or release. If substrate site is occupied, 
Met20 loop is found in occlude conformation. Binding of nicotamide ring of NADPH 
leads close conformation of Met20 loop. Transition of Met20 loop between these 
conformations disrupts preexisting hydrogen bond and forms new ones. [18] Upon 
cofactor binding, hydrogen bonds between Asn23 in Met20 loop and Ser148 in G-H 
loop are broken and new hydrogen bonds between Asp122 in FG loop and Ile14-Gly15-
Glu17. Therefore, these residues are very significant for ligand and cofactor binding. 
However, we did not see any mutation on these residues and also we did not found any 
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mutated residues on in F-G loop or G-H loop suggesting DHFR catalytic reaction have 
not been disturb by any kind of change.  
 
 
Figure 39a: Mutation Frequency of M20I versus days. It is only found in mild selection. 
Black color belongs to mild selection and red color corresponds to strong selection. 
Only exceptions are M20 and P21 residues on Met 20 loop. If we concentrate on 
M20I SNPs even if this mutation have not been observed in final destination of any 
culture, Methionine to Isoleucine change increases residue hydrophobicity (Appendix b) 
and M20I mutation might enables to protect the active site cleft which is found in very 
deep hydophobic region.  This mutation type was only observed in mild selection 
culture (culture 4) with mutation g-9a+D27E+F153V+M20I during day 10-14 (Figure 
39a). However M20I has competed with L28R and has failed in same background. 
Perhaps this faillure is due to slowest catalytic activity of DHFR because more 
hydrophobic residue might disrupt the flexibility of Met20 loop reflecting to fitness of 
bacteria.  
 
 
Figure 39b: Mutation Frequency of P21Q and P21L versus days. It is only found in 
strong selection. Black color belongs to mild selection and red color corresponds to 
strong selection.P21Q is more persistent than P21L 
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On the other hand, P21 residue is very close to M20. Similar with M20I, Both 
P21Q and P21L are not permanent in population (Figure 39b). Proline is non polar 
amino acid and in the case of P21Q, it is changed into glutamine which is polar but less 
hydrophobic than proline but Leucine is non polar and more hydrophobic than proline 
(Appendix B). P21L possesses very similar residue transition to M20I and it is also 
compete with L28R. Therefore, it also supports assumption about disruptions of Met20 
loop flexibility. If it is more hydrophobic, it may be attracted by hydrophobic active 
cleft. Additionally, P21Q is more persistent than P21L and it turns into polar and less 
hydrophobic residue (Figure 39b – Appendix B). However, since their background 
mutations are not same, we cannot compare them.  
Consequently, P21 and M20 residues are located on LoopI and mutations on 
these residues have large impacts on fitness of population  
 
Figure 40: Catalytic cycle of DHFR composed of 5 intermediate complexes. Purple 
rectangles correspond to DHFR enzyme [18] 
 
 NMR studies shows that Dynamical fluctuation of DHFR is related to ligand 
binding cofactor binding. The kinetic cycle of DHFR consists of 5 intermediate 
complexes. Holoenzyme (DHFR+NADPH) intermediate   enables to bind substrate 
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DHF and forms Michaelis Complex (DHFR+DHF+NADPH). Catalization occurs and 
DHFR+THF+NADP+ complex is generated and NADP+ is released.   However, 
substrate cannot leave from enzyme unless another NADPH cofactor binds to DHFR, 
which is rate limiting step of catalytic reaction. As result other intermediate 
DHFR+THF+NADPH is emanated and THF is released.  In physiological condition 
enzyme never gets free and D27 residue plays very important role in substrate release. It 
is responsible from hydride transfer to THF for its freedom (Figure 40) [18]. In our 
result we identified also D27E mutation nearly in every culture and four of them harbor 
this mutation in final genotype. However, if the amino acid properties of both native 
and mutant version of residue 27is investigated, it is inevitable to unnotice that both 
amino acid shares same characteristic. Both glutamic acid and aspartic acid amino acids 
are acidic polar and their hyrophobicity scale of site chains are same. Therefore bacteria 
populations may choose this conversion to decrease specificity of TMP binding without 
damaging to hydride transfer of 27th residue.  
FolA gene is situated between 49823-50302 positions of MG1655 e.coli 
genome. In close proximity of FolA gene, REP5 is located between50328-50364 
position. Mutation that we found in 34 nucleotide upstream of folA gene is then located 
on REP5. REP5 is repetitive extragenic palindromic sequence and these classes of 
repeats are known to have regulatory functions such as binding site for protein, cleavage 
site for DNA gyrase, stabilization of mRNA or transcriptional termination [25]. Arising 
of this mutation against TMP rises a question that this element may be related to 
transcription termination of FolA gene and this mutation may have stabilizing effect on 
mRNA of DHFR protein.  
Bacterial transcriptional termination can be intrinsic or rho factor independent. 
About half of genes have intrinsic termination in e.coli but transcription termination of 
other half are rho dependent. Transcription termination of Fol A gene depends on 
whether Rho factor or not is unknown.  In intrinsic termination, palindromic region after 
the stop codon of gene forms hairpin structure. Uracil rich region is found in 7-9 
nucleotides after hairpin structure where RNA polymerase is stabilized and stops. Both 
hairpin and the sequence located in both upstream and downstream of hairpin effects the 
termination efficiency. [26] Therefore +34 mutation may enables more efficient 
termination. If transcription termination is Rho dependent, Rho protein binds its binding 
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sites called rut site located in upstream of gene stop codon. Rho factor tracks along the 
DNA until it finds RNA polymerase.[26] +34 regions may be found in rut site of Rho 
factor and it may help stability of Rho binding. In order to understand of +34 SNPs 
function, transcriptional termination type of folA gene should be determined via hairpin 
modelization of target sequence and if transcription termination is Rho dependent, near 
proximity of +34 position may be deleted or site directly mutated to find rut site. 
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6. CONCLUSION 
 Evolution occurs via continuous adaptive mutations. Selection of adaptive 
mutation is where the resistance of microorganism begins. In order to analyze such 
origin of resistance, we designed morbidostat which is computer controlled selection 
device. We focused especially to trimethoprim resistance. Wherefore, we evolved 13 
cultures against Trimethoprim (TMP) by using morbidostat. We used mild and strong   
dilutions to understand evolutionary process and mutational trajectories of Mcherry 
Chloramphenicol resistant MG1655 E. coli strains. Chloramphenicol and Mcherry 
marker was used to prevent contamination risk of population. We arranged 6 cultures 
for mild selection and 7 cultures for strong selection by changing drug adding time as 
30sec and 60sec respectively. We have maintained experiments for 504 hours = 23 days 
and generated at least 1000 fold resistant E. coli strains against TMP.  
So as to identify the order and final destination of those spontaneous mutation 
acquisitions, we sequenced approximately 1300 single colony sequencing and   we 
found 4 promoter mutation and 13 distinct coding region mutation of DHFR. 
Interestingly, one novel mutation was detected on the +34 nucleotide upstream of 
DHFR gene of e.coli. Therefore, totally 18 spontaneous mutations were identified.We 
concluded that mutation combinations were not specific to dilution type. In addition, we 
measured population dynamics with f statistics. We found out dilution types induce 
more mutational pathways such that the order of mutation gaining was very explicit in 
mild dilution whereas the strongly diluted cultures tried many mutational pathways at 
the same time. We also espied that the promoter mutation have come first with 12/13 
ratio because bacteria prefered to change firstly expression of DHFR rather than 
changing protein structure.  
 Besides, in order to find fitness of mutations and their epistasic interaction, we 
restricted the growth with certain threshold and bacteria which possess lower growth 
rate than dilution rate have been eliminated. As a result, we compared the 
reproducibility of some mutation between each other. Apart from, we prolonged the 
experiment time to 600hours (27 days) to be sure about final destination and we found 
that nothing has changed.   
56 
 
 
 We accomplished Statistical Coupling Analysis (SCA) and scrutinized 
evolutionary conserved coevolving residues (sectors) of DHFR and we noticed that 
sectors were highly hit after the promoter mutation except tryptophan found in 30th 
residue.  Correspondingly, we made an interference that mutation acquisition has flown 
an ordered path starting with promoter mutation, following with sector region and 
finalizing with epistatis. 
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7. FUTURE WORKS 
 As a result of this study, we would like to suggest some future works to do. First 
of all, we analyzed population dynamics as a consequence of spontaneous mutation in 
Fol A gene but we did not performed whole genome sequencing to ensure the 
background of cultures. Therefore, WGS should be the first part of future experiments 
Secondly; replaying experiments may be designed to find out future step of population, 
after accumulation of predetermined mutation. Besides, pair wise interactions and 
fitness of mutations may be measured if strains are artificially mutated with P1 
transduction. Additionally, expression level of DHFR protein might be measured for 
each mutation or combination of mutations.  Finally, biochemical characterization 
DHFR enzyme may be investigated in mutational background with X-ray or NMR and 
catalytic efficiency of DHFR may be measured by determining kcat and km values 
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APPENDIX 
 
Appendix A 
Master Plate 1 
 
Master Plate 2 
 
 
  
61 
 
 
Master Plate 3 
 
Master Plate 4 
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Appendix B 
Culture 1 
 
Culture 2 
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Culture 3 
 
 
Culture 4 
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Culture 6 
 
Culture 7 
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Culture 8 
 
Culture 9 
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Culture 10 
 
Culture 11 
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Culture 13 
 
Culture 14 
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Culture 15 
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Appendix C 
FRS analysis of Mildly Diluted  Cultures 
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FRS analysis of Strongly Diluted  Cultures 
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Appendix D 
 
 
Adapted from a reference [27] 
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Adapted from a reference [27] 
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Appendix E 
Sequencing Results 
Culture 1 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a 
Colony 2 g-31a 
Colony 3 g-31a 
Colony 4 g-31a 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
Day 11 (4 different single colonies were sent to sequencing but one did not work well) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
 
Day 12 (4 different single colonies were sent to sequencing but one did not work well) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/c-35t 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
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Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
Colony 5 g-31a/L28R/A26T 
Colony 6 g-31a/L28R/A26T 
Colony 7 g-31a/L28R/A26T 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Culture 2 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
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Colony 4 No mutation 
 
Day 3 (4 different single colonies were sent to sequencing but one did not work well) 
Colony 1 D27E 
Colony 2 D27E 
Colony 3 D27E 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 D27E 
Colony 2 D27E 
Colony 3 D27E 
Colony 4 D27E 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a 
Colony 2 D27E/g-9a 
Colony 3 D27E/g-9a 
Colony 4 D27E/g-9a 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153V 
Colony 2 D27E/g-9a/F153V 
Colony 3 D27E/g-9a/F153V 
Colony 4 D27E/g-9a/F153V 
 
Day 11 (4 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153V 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153V 
 
Day 12 (4 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
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Day 19 (8 different single colonies were sent to sequencing but one did not work well) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
Colony 5 D27E/g-9a/F153S 
Colony 6 D27E/g-9a/F153S 
Colony 7 D27E/g-9a/F153S 
 
Day 20 (8 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
Colony 5 D27E/g-9a/F153S 
Colony 6 D27E/g-9a/F153S 
Colony 7 D27E/g-9a/F153S 
Colony 8 D27E/g-9a/F153S 
 
Day 21 (8 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
Colony 5 D27E/g-9a/F153S 
Colony 6 D27E/g-9a/F153S 
Colony 7 D27E/g-9a/F153S 
Colony 8 D27E/g-9a/F153S 
 
Day 22 (8 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
Colony 5 D27E/g-9a/F153S 
Colony 6 D27E/g-9a/F153S 
Colony 7 D27E/g-9a/F153S 
Colony 8 D27E/g-9a/F153S 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 D27E/g-9a/F153S 
Colony 2 D27E/g-9a/F153S 
Colony 3 D27E/g-9a/F153S 
Colony 4 D27E/g-9a/F153S 
Colony 5 D27E/g-9a/F153S 
Colony 6 D27E/g-9a/F153S 
Colony 7 D27E/g-9a/F153S 
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Culture 3 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-9a 
Colony 3 g-9a 
Colony 4 g-9a 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-9a 
Colony 3 g-9a 
Colony 4 g-9a 
 
Day 8 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-9a 
Colony 3 g-9a/W30C 
Colony 4 g-9a 
 
Day 9 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S 
Colony 2 g-9a/F153S 
Colony 3 g-9a/W30C 
Colony 4 g-9a/W30C 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S 
Colony 2 g-9a/F153S 
Colony 3 g-9a/W30S 
Colony 4 g-9a/W30C 
 
 
Day 11 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S 
Colony 2 g-9a/F153S 
Colony 3 g-9a/F153S 
Colony 4 g-9a/F153S 
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Day 12 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
Colony 5 g-9a/F153S/D27E 
Colony 6 g-9a/F153S/D27E 
Colony 7 g-9a/F153S/D27E 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
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Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/F153S/D27E 
Colony 2 g-9a/F153S/D27E 
Colony 3 g-9a/F153S/D27E 
Colony 4 g-9a/F153S/D27E 
 
Culture 4 Sequencing Results 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-9a 
Colony 3 g-9a 
Colony 4 g-9a 
 
Day 5 (4 different single colonies were sent to sequencing but one did not work well) 
Colony 1 c-35t 
Colony 2 g-9a/D27E 
Colony 3 g-9a/D27E 
 
Day 6 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E 
Colony 2 g-9a/D27E 
Colony 3 g-9a/D27E 
Colony 4 g-9a/D27E 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V 
Colony 2 g-9a/D27E/F153V 
Colony 3 g-9a/D27E/F153V 
Colony 4 g-9a/D27E/F153V 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V 
Colony 2 g-9a/D27E/F153V 
Colony 3 g-9a/D27E/F153V 
Colony 4 g-9a/D27E/F153V 
 
Day 11 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/M20I 
Colony 2 g-9a/D27E/F153V 
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Colony 3 g-9a/D27E/F153V 
Colony 4 g-9a/D27E/F153V 
 
Day 11 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/M20I 
Colony 2 g-9a/D27E/F153V 
Colony 3 g-9a/D27E/F153V/M20I 
Colony 4 g-9a/D27E/F153V 
 
Day 12 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/M20I 
Colony 2 g-9a/D27E/F153V 
Colony 3 g-9a/D27E/F153V/M20I 
Colony 4 g-9a/D27E/F153V 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/M20I 
Colony 2 g-9a/D27E/F153V 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V 
 
Day 14 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Day 15 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
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Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
Colony 5 g-9a/D27E/F153V/L28R 
Colony 6 g-9a/D27E/F153V/L28R 
Colony 7 g-9a/D27E/F153V/L28R 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/D27E/F153V/L28R 
Colony 2 g-9a/D27E/F153V/L28R 
Colony 3 g-9a/D27E/F153V/L28R 
Colony 4 g-9a/D27E/F153V/L28R 
 
Culture 6 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R 
Colony 2 c-35t/W30R 
Colony 3 c-35t/W30R 
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Colony 4 c-35t/W30R 
 
Day 8 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L 
Colony 2 c-35t/W30R/I94L 
Colony 3 c-35t/W30R/I94L 
Colony 4 c-35t/W30R/I94L 
 
Day 9 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L 
Colony 2 c-35t/W30R/I94L 
Colony 3 c-35t/W30R/I94L 
Colony 4 c-35t/W30R/I94L 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L 
Colony 2 c-35t/W30R/I94L 
Colony 3 c-35t/W30R/I94L 
Colony 4 c-35t/W30R/I94L 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L 
Colony 2 c-35t/W30R/I94L 
Colony 3 c-35t/W30R/I94L 
Colony 4 c-35t/W30R/I94L 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L/A26T 
Colony 2 c-35t/W30R/I94L/A26T 
Colony 3 c-35t/W30R/I94L/A26T 
Colony 4 c-35t/W30R/I94L/A26T 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L/A26T 
Colony 2 c-35t/W30R/I94L/A26T 
Colony 3 c-35t/W30R/I94L/A26T 
Colony 4 c-35t/W30R/I94L/A26T 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L/A26T 
Colony 2 c-35t/W30R/I94L/A26T 
Colony 3 c-35t/W30R/I94L/A26T 
Colony 4 c-35t/W30R/I94L/A26T 
Colony 5 c-35t/W30R/I94L/A26T 
Colony 6 c-35t/W30R/I94L/A26T 
Colony 7 c-35t/W30R/I94L/A26T 
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Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L/A26T 
Colony 2 c-35t/W30R/I94L/A26T 
Colony 3 c-35t/W30R/I94L/A26T 
Colony 4 c-35t/W30R/I94L/A26T 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L/A26T 
Colony 2 c-35t/W30R/I94L/A26T 
Colony 3 c-35t/W30R/I94L/A26T 
Colony 4 c-35t/W30R/I94L/A26T 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L/A26T 
Colony 2 c-35t/W30R/I94L/A26T 
Colony 3 c-35t/W30R/I94L/A26T 
Colony 4 c-35t/W30R/I94L/A26T 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/I94L/A26T 
Colony 2 c-35t/W30R/I94L/A26T 
Colony 3 c-35t/W30R/I94L/A26T 
Colony 4 c-35t/W30R/I94L/A26T 
 
Culture 7 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 5 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 6 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G 
Colony 2 c-35t/W30G 
Colony 3 c-35t/W30G 
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Colony 4 c-35t/W30G 
 
Day 7 ( 8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G 
Colony 2 c-35t/W30G 
Colony 3 c-35t/W30G 
Colony 4 c-35t/W30G 
Colony 5 c-35t/W30G 
Colony 6 c-35t/D27E 
Colony 7 c-35t/D27E 
Colony 8 c-35t/D27E 
 
Day 8 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G 
Colony 2 c-35t/W30G 
Colony 3 c-35t/W30G 
Colony 4 c-35t/W30G 
Colony 5 c-35t/D27E 
Colony 6 c-35t/D27E 
Colony 7 c-35t/D27E 
Colony 8 c-35t/D27E 
 
Day 9 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T 
Colony 2 c-35t/W30G/A26T 
Colony 3 c-35t/W30G/A26T 
Colony 4 c-35t/W30G/A26T 
Colony 5 c-35t/W30G/A26T 
Colony 6 c-35t/W30G/A26T 
Colony 7 c-35t/W30G/D27E 
Colony 8 c-35t/D27E 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T 
Colony 2 c-35t/W30G/A26T 
Colony 3 c-35t/W30G/A26T 
Colony 4 c-35t/W30G/A26T 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T 
Colony 2 c-35t/W30G/A26T 
Colony 3 c-35t/W30G/A26T 
Colony 4 c-35t/W30G/A26T 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T/L28R 
Colony 2 c-35t/W30G/A26T/L28R 
Colony 3 c-35t/W30G/A26T/L28R 
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Colony 4 c-35t/W30G/A26T/L28R 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T/L28R 
Colony 2 c-35t/W30G/A26T/L28R 
Colony 3 c-35t/W30G/A26T/L28R 
Colony 4 c-35t/W30G/A26T/L28R 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T/L28R 
Colony 2 c-35t/W30G/A26T/L28R 
Colony 3 c-35t/W30G/A26T/L28R 
Colony 4 c-35t/W30G/A26T/L28R 
Colony 5 c-35t/W30G/A26T/L28R 
Colony 6 c-35t/W30G/A26T/L28R 
Colony 7 c-35t/W30G/A26T/L28R 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T/L28R 
Colony 2 c-35t/W30G/A26T/L28R 
Colony 3 c-35t/W30G/A26T/L28R 
Colony 4 c-35t/W30G/A26T/L28R 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T/L28R 
Colony 2 c-35t/W30G/A26T/L28R 
Colony 3 c-35t/W30G/A26T/L28R 
Colony 4 c-35t/W30G/A26T/L28R 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T/L28R 
Colony 2 c-35t/W30G/A26T/L28R 
Colony 3 c-35t/W30G/A26T/L28R 
Colony 4 c-35t/W30G/A26T/L28R 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T/L28R 
Colony 2 c-35t/W30G/A26T/L28R 
Colony 3 c-35t/W30G/A26T/L28R 
Colony 4 c-35t/W30G/A26T/L28R 
 
Culture 8 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
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Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 g-31a 
Colony 4 g-31a 
 
Day 5 (4 different single colonies were sent to sequencing but one did not work well) 
Colony 1 g-31a 
Colony 2 g-31a 
Colony 3 g-31a 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a 
Colony 2 g-31a 
Colony 3 g-31a/P21Q 
Colony 4 g-31a/P21Q 
 
Day 8 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
Day 9 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
87 
 
 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
Colony 5 g-31a/L28R/A26T 
Colony 6 g-31a/L28R/A26T 
Colony 7 g-31a/L28R/A26T 
 
Day 24 (4 different single colonies were sent to sequencing but one did not work well) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
 
Day 25 (4 different single colonies were sent to sequencing but one did not work well) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Culture 9 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
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Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 5 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 6 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G 
Colony 2 c-35t/W30G 
Colony 3 c-35t/W30G 
Colony 4 c-35t/D27E 
Colony 5 c-35t/D27E 
Colony 6 c-35t/F153S 
Colony 7 c-35t 
Colony 8 c-35t 
 
Day 7 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G 
Colony 2 c-35t/W30G 
Colony 3 c-35t/W30G 
Colony 4 c-35t/F153S 
Colony 5 c-35t/F153S 
Colony 6 c-35t/F153S 
Colony 7 c-35t/D27E 
Colony 8 c-35t 
 
Day 8 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G 
Colony 2 c-35t/W30G 
Colony 3 c-35t/W30G 
Colony 4 c-35t/F153S 
Colony 5 c-35t/F153S 
Colony 6 c-35t/F153S 
Colony 7 c-35t/F153S 
Colony 8 c-35t/D27E 
 
Day 9 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G 
Colony 2 c-35t/ F153S 
Colony 3 c-35t/ F153S 
Colony 4 c-35t/F153S 
Colony 5 c-35t/F153S 
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Colony 6 c-35t/F153S 
Colony 7 c-35t/F153S 
Colony 8 c-35t/ F153S 
 
Day 10 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T 
Colony 2 c-35t/W30G/A26T 
Colony 3 c-35t/W30G/A26T 
Colony 4 c-35t/W30G/A26T 
Colony 5 c-35t/W30G/A26T 
Colony 6 c-35t/W30G/A26T 
Colony 7 c-35t/F153S 
Colony 8 c-35t/ F153S 
 
Day 11 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T 
Colony 2 c-35t/W30G/A26T 
Colony 3 c-35t/W30G/A26T 
Colony 4 c-35t/W30G/A26T 
Colony 5 c-35t/W30G/A26T 
Colony 6 c-35t/W30G/A26T 
Colony 7 c-35t/F153S/D27E 
Colony 8 c-35t/ F153S 
 
Day 12 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T 
Colony 2 c-35t/W30G/A26T 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/F153S/D27E 
Colony 7 c-35t/F153S/D27E 
Colony 8 c-35t/F153S/D27E 
 
Day 13 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30G/A26T 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/L28R 
Colony 6 c-35t/F153S/L28R 
Colony 7 c-35t/F153S/L28R 
Colony 8 c-35t/F153S/L28R 
 
Day 14 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
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Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/F153S/L28R 
Colony 7 c-35t/F153S 
 
Day 15 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
Colony 5 c-35t/F153S/L28R 
Colony 6 c-35t/F153S/L28R 
Colony 7 c-35t/F153S/L28R 
Colony 8 c-35t/F153S/L28R 
 
Day 15 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/L28R 
Colony 2 c-35t/F153S/L28R 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
Colony 5 c-35t/F153S/L28R 
Colony 6 c-35t/F153S/L28R 
Colony 7 c-35t/F153S/L28R 
Colony 8 c-35t/F153S/L28R 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/L28R 
Colony 2 c-35t/F153S/L28R 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/L28R 
Colony 2 c-35t/F153S/L28R 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
Colony 5 c-35t/F153S/L28R 
Colony 6 c-35t/F153S/L28R 
Colony 7 c-35t/F153S/L28R 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/L28R 
Colony 2 c-35t/F153S/L28R 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/L28R 
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Colony 2 c-35t/F153S/L28R 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/L28R 
Colony 2 c-35t/F153S/L28R 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/L28R 
Colony 2 c-35t/F153S/L28R 
Colony 3 c-35t/F153S/L28R 
Colony 4 c-35t/F153S/L28R 
 
Culture 10 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 3 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-9a 
Colony 3 g-9a 
Colony 4 g-9a 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E 
Colony 2 c-35t/D27E 
Colony 3 c-35t/D27E 
Colony 4 c-35t/D27E 
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Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/F153V 
Colony 2 c-35t/D27E/F153V 
Colony 3 c-35t/D27E/F153V 
Colony 4 c-35t/D27E/F153V 
 
Day 14 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/F153V 
Colony 2 c-35t/D27E/F153V 
Colony 3 c-35t/D27E/F153V 
Colony 4 c-35t/D27E/F153V 
 
Day 15 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/F153V 
Colony 2 c-35t/D27E/F153V 
Colony 3 c-35t/D27E/L28R 
Colony 4 c-35t/D27E/L28R/F153L 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
 
Day 22 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
Colony 5 c-35t/D27E/L28R/F153L 
Colony 6 c-35t/D27E/L28R/F153L 
Colony 7 c-35t/D27E/L28R/F153L 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
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Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/D27E/L28R/F153L 
Colony 2 c-35t/D27E/L28R/F153L 
Colony 3 c-35t/D27E/L28R/F153L 
Colony 4 c-35t/D27E/L28R/F153L 
 
Culture 11 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-9a 
Colony 3 g-9a 
Colony 4 g-31a 
 
Day 5 (5 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-9a 
Colony 3 g-9a 
Colony 4 g-9a 
Colony 5 g-31a 
 
Day 6 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a 
Colony 2 g-31a 
Colony 3 g-31a 
Colony 4 g-31a 
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Day 7 (8 different single colonies were sent to sequencing) 
Colony 1 g-31a/P21L 
Colony 2 g-31a/P21L 
Colony 3 g-31a 
Colony 4 g-31a 
Colony 5 g-31a 
Colony 6 g-31a 
Colony 7 g-31a 
Colony 8 g-31a 
 
 
Day 8 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R 
Colony 2 g-9a/L28R 
Colony 3 g-9a/L28R 
Colony 4 g-9a/L28R 
 
Day 9 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R 
Colony 2 g-9a/L28R 
Colony 3 g-9a/L28R 
Colony 4 g-9a/L28R 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R 
Colony 2 g-9a/L28R 
Colony 3 g-9a/L28R 
Colony 4 g-9a/L28R 
 
Day 13 (8 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/A26T 
Colony 2 g-9a/L28R/A26T 
Colony 3 g-9a/L28R/A26T 
Colony 4 g-9a/L28R/A26T 
Colony 5 g-9a/L28R/A26T 
Colony 6 g-9a/L28R/A26T 
Colony 7 g-9a/L28R/A26T 
Colony 8 g-9a/L28R/F153S 
 
Day 14 (8 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/A26T 
Colony 2 g-9a/L28R/A26T 
Colony 3 g-9a/L28R/A26T 
Colony 4 g-9a/L28R/A26T 
Colony 5 g-9a/L28R/A26T 
Colony 6 g-9a/L28R/A26T 
Colony 7 g-9a/L28R 
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Colony 8 g-9a/L28R 
 
Day 15 (8 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
Colony 5 g-9a/L28R/F153S 
Colony 6 g-9a/L28R/F153S 
Colony 7 g-9a/L28R/F153S 
Colony 8 g-9a/L28R/A26T 
 
Day 16 (7different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/A26T 
Colony 2 g-9a/L28R/A26T 
Colony 3 g-9a/L28R/A26T 
Colony 4 g-9a/L28R/A26T 
Colony 5 g-9a/L28R/A26T 
Colony 6 g-9a/L28R/A26T 
Colony 7 g-9a/L28R/F153S 
 
Day 17 (8 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
Colony 5 g-9a/L28R/F153S 
Colony 6 g-9a/L28R/F153S 
Colony 7 g-9a/L28R/F153S 
Colony 8 g-9a/L28R/F153S 
 
Day 18 (8 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
Colony 5 g-9a/L28R/F153S 
Colony 6 g-9a/L28R/F153S 
Colony 7 g-9a/L28R/F153S 
Colony 8 g-9a/L28R/A26T 
 
Day 19 (8 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
Colony 5 g-9a/L28R/F153S 
Colony 6 g-9a/L28R/F153S 
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Colony 7 g-9a/L28R/F153S 
Colony 8 g-9a/L28R/F153S 
 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
Colony 5 g-9a/L28R/F153S 
Colony 6 g-9a/L28R/F153S 
Colony 7 g-9a/L28R/F153S 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 g-9a/L28R/F153S 
Colony 2 g-9a/L28R/F153S 
Colony 3 g-9a/L28R/F153S 
Colony 4 g-9a/L28R/F153S 
 
Culture 13 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
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Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 7 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R 
Colony 2 c-35t/W30R 
Colony 3 c-35t/W30R 
Colony 4 c-35t/W30R 
 
Day 8 (3 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R 
Colony 2 c-35t/W30R 
Colony 3 c-35t/W30R 
 
Day 9 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R 
Colony 2 c-35t/W30R 
Colony 3 c-35t/W30R 
Colony 4 c-35t/W30R 
Colony 5 c-35t/W30R 
Colony 6 c-35t/W30R 
Colony 7 c-35t/W30R 
Colony 8 c-35t/W30R 
 
Day 10 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R 
Colony 2 c-35t/W30R 
Colony 3 c-35t/W30R 
Colony 4 c-35t/W30R 
Colony 5 c-35t/W30R 
Colony 6 c-35t/W30R 
Colony 7 c-35t/W30R 
Colony 8 c-35t/W30R 
 
Day 11 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T 
Colony 2 c-35t/W30R/A26T 
Colony 3 c-35t/W30R/A26T 
Colony 4 c-35t/W30R/A26T 
Colony 5 c-35t/W30R/D27E 
Colony 6 c-35t/W30R 
Colony 7 c-35t/W30R 
Colony 8 g-31a/L28R 
 
Day 12 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T 
Colony 2 c-35t/W30R/A26T 
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Colony 3 c-35t/W30R/A26T 
Colony 4 c-35t/W30R/A26T 
Colony 5 c-35t/W30R/A26T 
Colony 6 c-35t/W30R/A26T 
Colony 7 g-31a/L28R 
 
Day 13 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T 
Colony 2 c-35t/W30R/A26T 
Colony 3 c-35t/W30R/A26T 
Colony 4 c-35t/W30R/A26T 
Colony 5 c-35t/W30R/A26T 
Colony 6 c-35t/W30R/A26T 
Colony 7 c-35t/W30R/A26T 
Colony 8 g-31a/L28R 
 
Day 14 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T 
Colony 2 c-35t/W30R/A26T 
Colony 3 c-35t/W30R/A26T 
Colony 4 c-35t/W30R/A26T 
Colony 5 c-35t/W30R/A26T 
Colony 6 c-35t/W30R/A26T 
Colony 7 g-31a/L28R 
 
Day 15 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T 
Colony 5 c-35t/W30R/A26T 
Colony 6 c-35t/W30R/A26T 
Colony 7 c-35t/W30R/A26T 
Colony 8 c-35t/W30R/A26T 
 
Day 16 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/A26T/R98P 
Colony 7 c-35t/W30R/A26T/R98P 
Colony 8 c-35t/W30R/F153S 
 
Day 17 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
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Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/A26T/R98P 
Colony 7 c-35t/W30R/F153S 
 
Day 18 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/F153S 
Colony 7 c-35t/W30R/F153S 
 
Day 19 (11 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/A26T/R98P 
Colony 7 c-35t/W30R/F153S 
Colony 8 c-35t/W30R/F153S 
Colony 9 c-35t/W30R/F153S 
Colony 10 c-35t/W30R/F153S 
Colony 11 c-35t/W30R/F153S 
 
Day 20 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/A26T/R98P 
Colony 7 c-35t/W30R/A26T/R98P 
Colony 8 c-35t/W30R/A26T/R98P 
 
Day 21 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/A26T/R98P 
Colony 7 c-35t/W30R/A26T/R98P 
Colony 8 c-35t/W30R/F153S 
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Day 22 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/A26T/R98P 
Colony 7 c-35t/W30R/A26T/R98P 
Colony 8 c-35t/W30R/A26T/R98P 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
Colony 5 c-35t/W30R/A26T/R98P 
Colony 6 c-35t/W30R/A26T/R98P 
Colony 7 c-35t/W30R/A26T/R98P 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R/A26T/R98P 
Colony 2 c-35t/W30R/A26T/R98P 
Colony 3 c-35t/W30R/A26T/R98P 
Colony 4 c-35t/W30R/A26T/R98P 
 
Culture 14 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
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Colony 3 No mutation 
Colony 4 No mutation 
 
Day 2 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 3 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
 
Day 4 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
Colony 5 c-35t 
Colony 6 c-35t 
Colony 7 c-35t 
Colony 8 c-35t 
 
Day 5 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30C 
Colony 2 c-35t/D27E 
Colony 3 c-35t 
Colony 4 c-35t 
Colony 5 c-35t 
Colony 6 c-35t 
Colony 7 c-35t 
Colony 8 c-35t 
 
Day 6 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30C 
Colony 2 c-35t/W30C 
Colony 3 c-35t/W30C 
Colony 4 c-35t/W30C 
Colony 5 c-35t/W30R 
Colony 6 c-35t/W30R 
Colony 7 c-35t/W30R 
 
Day 7 (8 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
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Colony 4 g-31a/L28R 
Colony 5 c-35t/W30C 
Colony 6 c-35t/W30C 
Colony 7 c-35t/W30R 
Colony 8 c-35t/W30R 
 
Day 8 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t/W30R 
Colony 3 c-35t/W30R 
Colony 4 c-35t/W30R 
 
Day 8 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/W30R 
Colony 2 c-35t/W30R 
Colony 3 c-35t/W30R 
Colony 4 c-35t/W30R 
 
Day 10 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R 
Colony 2 g-31a/L28R 
Colony 3 g-31a/L28R 
Colony 4 g-31a/L28R 
 
Day 13 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 16 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 19 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 21 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
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Day 22 (7 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
Colony 5 g-31a/L28R/A26T 
Colony 6 g-31a/L28R/A26T 
Colony 7 g-31a/L28R/A26T 
 
Day 23 (13 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
Colony 5 g-31a/L28R/A26T 
Colony 6 g-31a/L28R/A26T 
Colony 7 g-31a/L28R/A26T 
Colony 8 g-31a/L28R/A26T 
Colony 9 g-31a/L28R/A26T 
Colony 10 g-31a/L28R/A26T 
Colony 11 g-31a/L28R/A26T 
Colony 12 g-31a/L28R/A26T 
Colony 13 g-31a/L28R/A26T 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 g-31a/L28R/A26T 
Colony 2 g-31a/L28R/A26T 
Colony 3 g-31a/L28R/A26T 
Colony 4 g-31a/L28R/A26T 
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Culture 15 Sequencing Results 
 
Day 1 (4 different single colonies were sent to sequencing) 
Colony 1 No mutation 
Colony 2 No mutation 
Colony 3 No mutation 
Colony 4 No mutation 
 
Day 4 (5 different single colonies were sent to sequencing) 
Colony 1 c-15g 
Colony 2 c-15g 
Colony 3 c-15g 
Colony 4 c-15g 
Colony 5 c-15g 
 
Day 5 (4 different single colonies were sent to sequencing) 
Colony 1 P21Q 
Colony 2 P21Q 
Colony 3 P21Q 
Colony 4 P21Q 
 
Day 7 (8 different single colonies were sent to sequencing) 
Colony 1 c-15g 
Colony 2 c-15g 
Colony 3 c-15g 
Colony 4 c-35t 
Colony 5 c-35t 
Colony 6 c-35t 
Colony 7 c-35t 
Colony 8 No mutation 
 
Day 8 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
Colony 5 c-35t 
Colony 6 c-35t 
Colony 7 c-35t 
 
Day 9 (5different single colonies were sent to sequencing) 
Colony 1 c-35t/P21Q 
Colony 2 c-35t 
Colony 3 c-35t 
Colony 4 c-35t 
Colony 5 c-35t 
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Day 10 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/P21Q 
Colony 2 c-35t/P21Q 
Colony 3 c-35t/P21Q 
Colony 4 c-35t/F153S 
Colony 5 c-35t/F153S 
Colony 6 c-35t/F153S 
Colony 7 c-35t/F153S 
 
Day 11 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S 
Colony 2 c-35t/F153S 
Colony 3 c-35t/F153S 
Colony 4 c-35t/F153S 
Colony 5 c-35t/F153S 
Colony 6 c-35t/F153S 
Colony 7 c-35t/F153S 
Colony 8 c-35t/F153S 
 
Day 12 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S 
Colony 2 c-35t/F153S 
Colony 3 c-35t/F153S 
Colony 4 c-35t/F153S 
Colony 5 c-35t/F153S 
Colony 6 c-35t/F153S 
Colony 7 c-35t/F153S 
Colony 8 c-35t/F153S 
 
Day 13 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/L28R 
Colony 7 c-35t/L28R 
Colony 8 c-35t/L28R 
 
 
Day 14 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/F153S/D27E 
Colony 7 c-35t/F153S/D27E 
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Colony 8 c-35t/L28R/F153S 
 
Day 15 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/F153S/D27E 
Colony 7 c-35t/F153S/D27E 
Colony 8 c-35t/F153S/D27E 
 
Day 16 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/F153S/D27E 
Colony 7 c-35t/F153S/D27E 
Colony 8 c-35t/L28R/F153S 
 
Day 17 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/L28R/F153S 
Colony 7 c-35t/L28R/F153S 
Colony 8 c-35t/ F153S 
 
Day 18 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/F153S/D27E 
Colony 4 c-35t/F153S/D27E 
Colony 5 c-35t/F153S/D27E 
Colony 6 c-35t/F153S/D27E 
Colony 7 c-35t/L28R/F153S 
Colony 8 c-35t/ L28R/F153S 
 
Day 19 (8 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
Colony 5 c-35t/L28R/F153S 
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Colony 6 c-35t/L28R/F153S 
Colony 7 c-35t/L28R/F153S 
Colony 8 c-35t/ L28R/F153S 
 
Day 21 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
 
Day 22 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/L28R/F153S 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
 
Day 23 (7 different single colonies were sent to sequencing) 
Colony 1 c-35t/F153S/D27E 
Colony 2 c-35t/F153S/D27E 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
Colony 5 c-35t/L28R/F153S 
Colony 6 c-35t/L28R/F153S 
Colony 7 c-35t/L28R/F153S 
 
Day 24 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/L28R/F153S 
Colony 2 c-35t/L28R/F153S 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
 
Day 25 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/L28R/F153S 
Colony 2 c-35t/L28R/F153S 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
 
Day 26 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/L28R/F153S 
Colony 2 c-35t/L28R/F153S 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
 
Day 27 (4 different single colonies were sent to sequencing) 
Colony 1 c-35t/L28R/F153S 
Colony 2 c-35t/L28R/F153S 
Colony 3 c-35t/L28R/F153S 
Colony 4 c-35t/L28R/F153S 
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